Cargando…

Current landscape of clinical trials for HPV-positive head and neck squamous cell carcinoma (HNSCC)

This study aims to determine the current state of clinical trials regarding HPV-positive head and neck squamous cell carcinoma (HNSCC). Clinical trials were filtered to fit the study’s aim using Clinicaltrials.gov: trials concerning HNSCC specifically those related to HPV done between January 2005 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bteich, Yara T, Hosri, Jad E, Wehbi, Jad A, Daou, Lea R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666285/
https://www.ncbi.nlm.nih.gov/pubmed/36405940
http://dx.doi.org/10.3332/ecancer.2022.1447
_version_ 1784831470565588992
author Bteich, Yara T
Hosri, Jad E
Wehbi, Jad A
Daou, Lea R
author_facet Bteich, Yara T
Hosri, Jad E
Wehbi, Jad A
Daou, Lea R
author_sort Bteich, Yara T
collection PubMed
description This study aims to determine the current state of clinical trials regarding HPV-positive head and neck squamous cell carcinoma (HNSCC). Clinical trials were filtered to fit the study’s aim using Clinicaltrials.gov: trials concerning HNSCC specifically those related to HPV done between January 2005 and December 2020 were extracted and information regarding location, duration, phases, patient recruitment, trial status, results, primary outcome, type of intervention and publication status were collected and analysed. As a result, 123 trials were included. North American countries (USA and Canada) conducted more than two-thirds of the trials (72.4%) compared to European countries and the rest of the world. Trials in phase II constituted more than half of those included in this study (53.7%). From the 123 trials included in this study, only 30 had their NCT identification number linked to publications, but less than half (46.7%) of the publications stemmed from trials with results. Drug combination was the most widely studied treatment modality. Despite falling in the middle of the spectrum with respect to the number of trials when compared to other diseases, our research highlights the need for even more trials tackling multiple aspects of HPV-positive HNSCC.
format Online
Article
Text
id pubmed-9666285
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-96662852022-11-18 Current landscape of clinical trials for HPV-positive head and neck squamous cell carcinoma (HNSCC) Bteich, Yara T Hosri, Jad E Wehbi, Jad A Daou, Lea R Ecancermedicalscience Research This study aims to determine the current state of clinical trials regarding HPV-positive head and neck squamous cell carcinoma (HNSCC). Clinical trials were filtered to fit the study’s aim using Clinicaltrials.gov: trials concerning HNSCC specifically those related to HPV done between January 2005 and December 2020 were extracted and information regarding location, duration, phases, patient recruitment, trial status, results, primary outcome, type of intervention and publication status were collected and analysed. As a result, 123 trials were included. North American countries (USA and Canada) conducted more than two-thirds of the trials (72.4%) compared to European countries and the rest of the world. Trials in phase II constituted more than half of those included in this study (53.7%). From the 123 trials included in this study, only 30 had their NCT identification number linked to publications, but less than half (46.7%) of the publications stemmed from trials with results. Drug combination was the most widely studied treatment modality. Despite falling in the middle of the spectrum with respect to the number of trials when compared to other diseases, our research highlights the need for even more trials tackling multiple aspects of HPV-positive HNSCC. Cancer Intelligence 2022-09-20 /pmc/articles/PMC9666285/ /pubmed/36405940 http://dx.doi.org/10.3332/ecancer.2022.1447 Text en © the authors; licensee ecancermedicalscience. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Bteich, Yara T
Hosri, Jad E
Wehbi, Jad A
Daou, Lea R
Current landscape of clinical trials for HPV-positive head and neck squamous cell carcinoma (HNSCC)
title Current landscape of clinical trials for HPV-positive head and neck squamous cell carcinoma (HNSCC)
title_full Current landscape of clinical trials for HPV-positive head and neck squamous cell carcinoma (HNSCC)
title_fullStr Current landscape of clinical trials for HPV-positive head and neck squamous cell carcinoma (HNSCC)
title_full_unstemmed Current landscape of clinical trials for HPV-positive head and neck squamous cell carcinoma (HNSCC)
title_short Current landscape of clinical trials for HPV-positive head and neck squamous cell carcinoma (HNSCC)
title_sort current landscape of clinical trials for hpv-positive head and neck squamous cell carcinoma (hnscc)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666285/
https://www.ncbi.nlm.nih.gov/pubmed/36405940
http://dx.doi.org/10.3332/ecancer.2022.1447
work_keys_str_mv AT bteichyarat currentlandscapeofclinicaltrialsforhpvpositiveheadandnecksquamouscellcarcinomahnscc
AT hosrijade currentlandscapeofclinicaltrialsforhpvpositiveheadandnecksquamouscellcarcinomahnscc
AT wehbijada currentlandscapeofclinicaltrialsforhpvpositiveheadandnecksquamouscellcarcinomahnscc
AT daoulear currentlandscapeofclinicaltrialsforhpvpositiveheadandnecksquamouscellcarcinomahnscc